A computer-based markov decision analysis of the management of symptomatic bifascicular block: The threshold probability for pacing  by Robert Beck, J. et al.
920 lACC Vol. 9. No, 4
April 1987:920- 35
SEMINAR ON COMPUTER APPLICATIONS FOR THE CARDIOLOGIST-V
Edward A. Geiser, MD, FACC, David J. Skorton, MD, FACC, Guest Editors
A Computer-Based Markov Decision Analysis of the Management of
Symptomatic Bifascicular Block: The Threshold Probability for Pacing*
J. ROB ERT BECK, MD,t ,* DEEB N. SALEM , MD, FACe, t N. A. MARK ESTES, MD, FACC,t
STEPHEN G. PAUKER, MD, FACCt ,:!:
Boston. Massachusetts
This review illustrates the use of computer-based Mar-
kov models to estimate cost-effectiveness and prognosis
in a complex problem in clinical cardiology.
Decision analysis and cost-effectiveness analysis were
used to assess whether to implant a permanent cardiac
pacemaker, treat with drugs, perform electrophysiologic
studies or obser ve patients who have two clinical fea-
tures-syncope and bifascicular block-that mayor may
not be causally related. Using a Markov process model,
a computer program simulated the prognosis of five co-
horts of such patients-one treated conservatively, one
given empiric antiarrhythmic drug therapy, one receiv-
ing a pacemaker, one tr eated with empiric drugs and
pacing and one tested with electrophysiologic studies.
On the basis of data from published reports and expert
opinion, quality-adjusted life expectancy was calculated
by summing the average time a member of each cohort
would survive with and without symptoms for each ini-
Both medical ( 1- 7) and lay pub lications (8- 12) have sug-
gested that physicians implant permanent transvenous car-
diac pacem akers too often. Th e conclusions of the physician
expe rts in these critical articles have been based on pro-
spec tive and retrospective case by case analyses. These
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tial treatment choice. The costs were estimated from
1985 hospital charges.
For patients with normal left ventricular function ,
electrophysiologic testing provides a benefit of 14 qual-
ity-adj usted months of life over obser vation , at an ad-
ditional cost of $24,200. Empiric pacing would add 2.5
additional months, at a further cost of $14,300. In pa-
tients with poor left ventricular function, empiric drug
therapy offers 1.5 additional quality-adjusted months
over observation, at a cost of $6,900. Electrophysiologic
testing provides a further 16.5 months at an additional
cost of $16.900. These results hold when the relation
between symptoms and arrhythmia is not firmly estab-
lished. Varying the probabilities of underl ying ventric-
ular tachyarrhythmias, bradyarrhythmic conduction
defects or noncardiac causes of syncope affects the cost-
effectiveness relative to the alternative treatments.
(J A m Colt Cardiol 1987;9:920-35)
opinions have not , however , include d a quantitative bal-
ancing of the costs and risks of not implanting a pacemaker.
in patients whose symptoms could be allevia ted and whose
survival could be prolonged by such therapy. agai nst the
risks of implanting a pacemaker. in patients who rea lly do
not requ ire one . Thi s problem is well suited to clini cal
decision analys is (13- 17) becau se the decision to employ
a pacemaker should rest on a comparison of the benefits .
risks and costs of a pacemaker with respect to the probabilit y
that pacemaker-responsive sym ptoms are present.
We addressed the specific question: in which patients
with both syncope and bifascicular block should a pace-
maker be inserted? Clearly , some patients have both find-
ings : in some the symptoms are cau sally related to the con-
duction disturbance , and in others they are not. The risks
of pace maker therapy are low. but pacemakers are expen-
sive , Nevertheless, patients with symptoms responsive to
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pacemaker implantation experience substantial gains in both
survival and quality of life if a pacemaker is used (18). On
the other hand, the omission of electrophysiologic testing
may lead to inappropriate therapy in some patients with
ventricular tachyarrhythmias. Thus, the quality-adjusted
survival of some patients with symptoms causally related
to arrhythmias will improve if their physicians implant a
pacemaker before a relation between arrhythmia and symp-
toms is documentedunequivocally, while other patients will
be at additional risk for sudden death. In this study we
analyze the benefits and risks of early pacemaker implan-
tation in terms of quality-adjusted life expectancy and cal-
culate the expected monetary costs of such therapy, com-
pared with alternatives of empiric drug therapy and
electrophysiologic diagnostic studies.
The data base on which physicians' decisions in this area
rest is weak fo r several reasons. First. studies of the "nat-
ural history" of bifascicular block and other conduction
disturbances often exclude patients with syncope and ter-
minate follow-up when a pacemaker is implanted. Second,
there has been no randomized controlled prospective trial
of pacemaker therapy in such patients. Third, although bi-
fascicular block can evolve into high degrees of atrioven-
tricular (AV) block, patients with such advanced conduction
disturbances are now uniformly treated by pacemaker im-
plantation. Thus, contemporary natural history data in pa-
tients with high grade AV block are sparse.
Given current clinical practice, the data base describing
the natural history of high grade conduction disturbances is
unlikely to increase substantially, and our present study
cannot improve that data base. Rather, we develop a prog-
nostic model that utilizes the available data and shows under
what range of assumptions the strategy of aggressive pace-
maker implantation would be optimal.
Review of the Literature
In bifascicular block, as in any disorder of cardiac con-
duction, clinical concern centers around the possibility of
cardiac slowing sufficient to cause syncope or sudden death.
Table I. Reported Prognosis of Chronic Bifascicular Heart Block
Prophylactic pacemaker insertion might prevent brady-
arrhythmias, but it is costly and associated with some risk.
The Framingham study (1 9) of 5, 176 persons over age 18
years accumulated 125 cases of new left or right bundle
branch block, or both , in 18 years. that is, 134 casesllOO,OOO
patients per year. Thus, even if pacemaker insertion were
risk free. the economic costs of prophylactic pacemaker
insertion in all patients with newly acquired bundle branch
block would be prohibitive. The current approach has been
to identify patients with " high risk" conduction abnor-
malities (20). Little attention has been devoted, however,
to defining the risk-benefit relation of early pacemaker im-
plantation.
Risks of chronic bifascicular block. Although patients
with chronic bifascicular heart block may develop AV block ,
this risk appears to be relatively low (19,2 1). Table I sum-
marizes the results of two retrospective (22 .23) and four
prospective (24-26) studies involving 1,566 patients over
an average of 2.9 years. Only 65 deaths possibly related to
AV block (4.2%) were observed. although there wasa 16.6%
annual incidence rate of pacemaker insertion during the
follow-up periods. The high prevalence of other cardiovas-
cular diseases probabl y accounted for the high overall mor-
tality (26) . The rates of progression to complete heart block
were also low. averaging 5% over the follow-up period.
Some studies did not report symptoms. but those containing
such data (23.24 ,26) included 85 patients, of whom roughly
half had symptoms that could reasonably be attributed to
AV block.
III patients with bifascicular block with prior syncope.
however, the risk of progression to complete AV block is
higher than in asymptomatic patients with bifascicular block.
Of the 554 patients followed up by McAnulty et al. (26).
a subgroup of 47 persons had syncope at some time before
entry into the study and 8 had syncope at the time of entry
into the study. The syncope was determined to be secondary
to heart block in none of these 55 individuals. During a
mean follow-up period of 42.4 months there was a 17%
incidence rate of heart block in individuals with syncope.
compared with a 2% incidence rate in those without syncope
Death Symptom s Symptoms
No. Possibly Probably Probably
of Follow Caused by Caused by Not Caused by
Study Patient s Up (yr) Dead AV Block Bradyarrhythmia Bradyarrh ythmia Paced AV Block
Scanlon (22) 209 2 3\ 3( 1.4%) 30(14.4%)
DePasquale (23) 83 3. \ 19 I ( l.2'k) 5(6 .0% ) 30 .6%) 5 2(2 .5%)
Narula (24) 83 3 32 I ( 1.29f) 19(22 .9°k) II I 13.6%) 28 4(4 .8%)
Dhingra (25) 53 1 3.3 207 42(7.9% ) 32 2 1(4.0%)
Kulbertu s (25a) 106 3 10 0 2( 1.1J%)
McAnult y (26) 554 3.5 160 IX(3.29i ) IIJ(3.4%) 28(5 .00/r) 30 19(3.4%)
Total t.566 2.9 459 65(4 .2'k ) 43(6 .0%) 42(5 .X%) 95 of 7X(5.0%)
of 720 of 720 752
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(p < 0.05). Additionally , sinoatrial disorders occurred in
18% of the patients with syncope. Like patients with AV
block, individuals with sinus node dysfunction would have
pacemaker-responsive symptoms but would not experience
prolonged survival.
In the subsequent analysis we shall assume that patients
with bifascicular block who develop high grade AV block
become subject to the same risks as patients who initially
present with AV block. Thus, the risks of high grade AV
block are considered next.
Risks of high grade AV block. Permanent ventricular
pacing has been the treatment of choice for high grade AV
block for 20 years; pacing has prolonged the life of patients
with this disorder. If underlying cardiovascular disease is
present, the expected survival of these patients, even with
permanent pacing, is less than thatof members of thegeneral
population of the same age (27,28) . Table 2 summarizes
the survival of 178 untreated patients (29,30) and 1,268
patients treated with pacemaker implantation (27- 33). The
limited availability of data describing the natural history of
high grade AV block reflects the worldwide acceptance of
pacemaker implantation as therapy for that entity. The 2
year survival rate for unpaced patientswas 45.5% compared
with 78.3% for patients treated with a pacemaker. The mor-
tality rate in these patients was related to underlying car-
diovascular disease, decreased cardiac output or congestive
heart failure and advanced age (Table 3) (28,30,31,33 ,34).
In a series composed largely, although not entirely, of
patientswith AV block, Furman(35) reported the long-term
survival of 1,500 patients receiving a pacemaker. The 2
year survival was 80%, survival at 5 years was 65% and
survivalat 10 years was40%. Hesuggested that theseresults
were comparable with those for members of the general
population of the same age and sex.
Thus. chronic bifascicular heart block has a relatively
good prognosis but can evolve into complete heart block.
a disorder with poor prognosis unless a pacemaker is in-
serted. Investigators have therefore examined techniques for
identifying patients at high risk for developing complete
heart block.
Predictive value of electrophysiologic testing. At pres-
ent, detailedrecommendations regardingthe role of invasive
electrophysiologic studies and evaluation of patients with
bifascicularblock and syncope are difficult to formulate, in
part because of the limitations inherent in published data
derived fromhighly selectedpatientpopulationsand to vari-
ation in testing protocols (36- 42). However, two recently
published studies (43,44) provide data that impact on the
role of electrophysiologic testing in the evaluation of pa-
tients with syncope and bifascicular block. Ezri et al. (43)
studied 13 patients using programmed ventricular stimula-
tion (six had coronary artery disease, three had cardio-
myopathy and four had no evidence of organic heart dis-
ease). Holter monitoring and neurologic evaluation were
nondiagnostic in all patients prior to electrophysiologic test-
ing. The resultsof the studies included inducibleventricular
Table 2. Reported Prognosis of High Grade AV Block
Unpaced Paced
No. of No. of
Study Patients Survival Patients Survival
Johansson (30) 119 50% (I yr) 101 87% (I yr)
44% (2 yr)
Mascarenhas (31) 230 79.6% (I yr)
72.2% (2 yr)
Amikam (32) 80 90% ( I yr)
82. 1% (2 yr)
5lU % (5 yr)
Rettig (27) 369 79.9% (2 yr)
65.6% (4 yr)
53.7% (6 yr)
Ohm (29) 59 63% (t yr) 122 87% (I yr)
47% (2 yr) 83% (2 yr)
Simon (28) 246 88% (I yr)
61% (5 yr)
49% (10 yr)
Alpert (33) 120 91% (I yr)
63% (5 yr)
49% (10 yr)
Total 178 56.5% ( I yr) 1268 85.9% ( I yr)
45 .5% (2 yr) 78.3 % (2 yr)
59.4 % (5 yr)
46.4 % (10 yr)
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Table 3. Reported Relation of Underlying Disease to Survival in Pacemaker Treated High Grade A V Block
No. of
Survival (%)
Study Underlying Disease Patients I Yr 2 Yr 5 Yr 10 Yr
Mascarenhas (31) Stokes-Adams alone 48 91.7 85.4
Stokes-Adams with decreased cardiac 118 83.9 77.9
output or congestive heart failure
No Stokes-Adams but complete heart 64 62.5 50
block with congestive heart failure
Simon (28) Congestive heart failure 89 85 75 55
No congestive heart failure 157 90 85 69
Idiopathic 113 87 72
Ischemic/hypertensive 67 65 40
Age < 65 86 75
Age 65 to 74 93 61
Age 20 75 67 40
Alpert (33) Conduction system disease only 46 92 79 68
Congestive heart failure 48 87 49 19
Age < 66 33 90 65 42
Age 66 to 74 34 87 64 43
Age 20 75 53 95 61 38
Coronary heart disease 35 89 51 28
Diabetes 29 97 68 41
Hypertension 14 89 63 35
Valvular heart disease 11 78 63 53
tachycardia in four patients, an HV interval greater than 70
ms in four, and intraHis and infraHis bundle block with
atrial pacing in one, and were nondiagnostic in four patients.
Four of the five patients with a prolonged HV interval or
pacing-induced infranodal block and one with a nondi-
agnostic study received a permanent pacemaker. The four
patients with ventricular tachycardia received antiarrhyth-
mic therapy, and three of the four patients with nondiagnos-
tic studies received no therapy. During a mean follow-up
period of 9 months, all but three patients had been free of
syncope. One patient did not take prescribed antiarrhythmic
therapy, another patient with ventricular tachycardia died
suddenly and the remaining patient had a normal study and
was eventually shown to have basilar migraines.
In a similar study, Morady et al. (44) identified abnormal
infranodal conduction times in 12 (38%) of 32 patients and
found pathologic infranodal block during atrial pacing in 2
(6%). Unimorphic ventricular tachycardia was induced in
nine patients (28%) and polymorphic ventricular tachycardia
in five (16%). In general, a permanent pacemaker was im-
planted in patients with infranodal block or a prolonged HV
interval. Patients with ventricular tachycardia were treated
with an antiarrhythmic drug. The mean follow-up period
was 19 months. There were three sudden deaths: in a non-
compliant patient with inducible sustained ventricular tachy-
cardia; in a patient treated empirically with quinidine for
premature ventricular complexes and in a patient with a
prolonged HV interval treated with a permanent pacemaker.
The actuarial incidence of sudden death was 10% at 45
months of follow-up. Only two patients had recurrent syn-
cope; both had a normal electrophysiologic study. Thus,
approximately 50% of patients with bundle branch block
and unexplained syncope who underwent electrophysiologic
testing were found to have at least one clinically significant
abnormality.
Although prospective, randomized therapy has not been
reported, approximately 85% of patients whose treatment
was based on the results of electrophysiologic testing did
not experience recurrent syncope. In 204 patients with syn-
cope not selected for bifascicular disease, Kapoor et al. (45)
identified a cardiovascular cause in 53 and a noncardiac
cause in 54. Of the 23 patients who underwent electro-
physiologic testing, 3 were found to have inducible ven-
tricular tachycardia not documented by electrocardiographic
monitoring, 2 had a prolonged HV interval, I patient with
clinical evidence of sick sinus syndrome had a prolonged
sinus node recovery time, 2 patients had inducible supra-
ventricular tachycardia, 3 had a nondiagnostic prolonged
effective refractory period of the AV node and 12 patients
had a nondiagnostic study. The therapy that was instituted
was based on these findings. After I year, the overall mor-
tality rate was 30% in patients with a cardiovascular cause
(24% incidence of sudden death), 12% in patients with
established noncardiac causes (4% incidence of sudden death)
and 6.4% in patients with syncope of unknown origin (3%
incidence of sudden death).
Although three prospective studies have failed to dem-
onstrate a consistent relation between progression of in-
franodal conduction system disease and electrophysiologic
testing results (26.46.47), the patient populations and the
924 BECK ET AL.
THRESHOLD FOR PACING IN BIFASCICULAR BLOCK
lACC Vol. 9, No.4
April 1987:920-35
PACING
Figure 1. Decision tree. Five strategiesare proposedfor the man-
agementof symptomatic bifascicularblock. Empiric pacing, anti-
arrhythmic drugs, both pacing and drugs and observation (OBS.)
lead to the distal chance node (circle) at right. Electrophysiologic
testing (EPS) leads to a first chance node (circle) at which the
appearance at electrophysiologic testing and the consequent man-
agement plans are described. BR = bradyarrhythmia; NAS
nonarrhythmic syncope; VT = ventricular tachyarrhythmia.
NAS
BOTHBR& vr"VT"·>ORUGS
"BR&VT"·>BOTH
NORMAL·>OBS.
"BR"·>PACING
EPS
OBSERVATION
DRUGS
BOTH PACING,DRUGS
study protocols were markedly different from those used by
Ezri and Morady and their colleagues (43,44). McAnulty
et al. (26) identified patients with conduction system disease
based on screening electrocardiograms. Any patient with
symptoms documented to be due to brady arrhythmia was
excluded and treated with a pacemaker. Similarly, Dhingra
et al. (46) found that 38% of 452 asymptomatic patients
with chronic conduction system disease had evidence of
impaired infranodal conduction. Peters et al. (47) analyzed
the clinical and serial electrophysiologic variables associated
with progressive disease in 90 patients undergoing at least
two electrophysiologic studies. Neither age, cardiac diag-
nosis, New York Heart Association classification, electro-
cardiographic patterns, nor initial abnormal infranodal con-
duction was a reliable marker for progression.
By contrast, Scheinman et al. (48) found a greater rate
of progression to second or third degree AV block in patients
with impaired infranodal conduction. Of 121 patients fol-
lowed up for a mean of 18 months, 21% with abnormal
infranodal conduction progressed to second or third degree
AV block as compared to 1.3% with normal infranodal
conduction.
In this review we will build an analytic computer model
of the decision to pace or treat empirically, to conduct elec-
trophysiologic testing or to observe a patient with chronic
bifascicular heart block and unexplained syncope, and will
compare the costs and medical effects of each proposed
strategy.
Methods
The problem. Consider a patient who presents with
repeated syncopal episodes without a clear precipitating cause.
The routine electrocardiogram demonstrates bifascicular
block. Ambulatory electrocardiographic monitoring fails to
demonstrate either AV block or bradycardia, but no syn-
copal episodes occurred during the 24 hour recording. (We
exclude patients who develop documented AV block or
bradycardia with syncope because they will surely receive
a pacemaker. We also exclude patients who develop their
typical syncope without documented arrhythmia because in
such cases the findings are most likely unrelated.) Should
a permanent pacemaker be implanted? Should electrophys-
iologic testing be performed? In this analysis we will con-
sider patients who have normal ventricular function sepa-
rately from those who have serious left ventricular disease,
because the spectrum and risks of arrhythmias differ.
Therapeutic approach. Five alternative strategies are
proposed for the problem of unexplained syncope in bilateral
bundle branch block (Fig. 1, left). 1) A patient may be
prophylactically paced, effectively abolishing the chance of
progressive heart block. 2) To treat possible ventricular
tachyarrhythmias, he or she may be given a trial of anti-
arrhythmic agents. 3) These therapies can be combined. 4)
A patient may be submitted to electrophysiologic testing,
or 5) observed for progression of arrhythmia. For anyone
of these strategies, the patients may have one of four pos-
sible causes of syncope (Fig. 1; right): bradycardic con-
duction defects, ventricular tachyarrhythmia, both causes,
or nonarrhythmic syncope.
If the decision is made to conduct electrophysiologic
testing. however, four results are possible: 1) A bradyar-
rhythmia (conduction delay) or block will be detected, lead-
ing to pacemaker implantation; 2) a ventricular tachyar-
rhythmia will be detected, leading to a trial of medication,
repeat studies and follow-up; 3) both conduction disease and
ventricular tachyarrhythmias will be identified, leading to
both types of treatment; or 4) electrophysiologic testing will
be normal. In the last event, we assume the diagnosis of
nonarrhythmic syncope will be made and the patient will
be treated conservatively (44). Of course, the electrophys-
iologic testing result will not always be correct; a proportion
of patients with each type of syncope will be falsely clas-
sified; thus, the results of electrophysiologic testing are shown
in quotes in Figure I.
Table 4 contains the data used in the decision tree, sub-
jectively obtained from an experienced clinical electrophy-
siologist. In patients with normal left ventricular function,
bradyarrhythmic conduction disturbances and noncardiac
lACC Vol. 9. No.4
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Table 4. Assumptions About Causes of Syncope and Appearance al Electrophysiologic Testing
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Appearance at Electrophysiologic Testing
Etiology
Prevalence
(fraction of cohort) BR VT Both NAS
A. Left Ventricular Ejection Fraction Normal
BR
VT
Both
NAS
0.50
0.10
0.05
0.35
0.60
0.25
0.20
0.20
0.10
0.55
0.20
0.05
0.05
0.10
0.30
0.05
0.25
0.10
0.30
0.70
B. Left Ventricular Ejection Fraction <40%; Coronary Disease With Prior MI
BR
VT
Both
NAS
0.25
0045
0.10
0.20
0040
0.05
0.05
0.10
0.15
0.65
0.35
0.20
0.20
0.25
0.55
0.05
0.25
0.05
0.05
0.65
Both = both ventriculartachyarrhythmia and bradyarrhythmia; BR = bradyarrhythmialconduction distur-
bance; MI = myocardial infarction; NAS = nonarrhythmic syncope; VT = ventricular tachyarrhythmia .
syncope are the most common etiology, occurring in 50%
and 35%, respectively, of a cohort of patients with chronic
bifascicular heart block and syncope. Electrophysiologic
testing identifies bradyarrhythmic lesions, ventricular tach-
yarrhythmias and nonarrhythmic syncope in more than half
of the cases. In patients with poor left ventricular function
and a cardiac history, ventricular tachyarrhythmia is the
etiology in almost half of the patients; in these, therefore,
electrophysiologic testing would be most sensitive to ven-
tricular tachyarrhythmias and combined etiologies. Under
all scenarios, the natural historyof the patient's arrhythmia,
underlying cardiovasculardisorders and co-morbidity must
be modeled. We model cardiac and noncardiac mortality
separately. We also keep a separate record of the frequency
and consequences of AV block.
Markov model. We will simulate the prognosis of not
one, but I million patients with the same findings. We
simulatedthe naturalhistory of this cohortof patients, using
a wellestablisheddecision theoretic approach-the Markov
process assumption (49). In this model, we assumed that a
patient's current age and state of health predict the future
behaviorof a cohort of similar patients (50). We calculated
the number of patients in each state and the number of
transitions among states that would be expected to occur
each month.
Using the Markov model, we performed separate com-
puter simulations for each disease and initial treatment op-
tion. For treatments not involving initial pacemaker im-
plantation(with or withoutantiarrhythmic drugs), we began
with a cohort of I million patients initially in a state labeled
"no AV block" ; we assumed that the cohort would be
followed up for the development of AV block. When AV
blockdevelops, a pacemakerwouldbe implanted. For treat-
ment involving initialpacemakerimplantation (withor with-
out drugs), we assumed that the cohort would be followed
up for the development of pacemakerfailure. We continued
each simulation until all members of each cohort were in
the state "dead ." Probabilities of sudden cardiac death de-
pendedon the underlying cause (that is, tachycardia, brady-
cardia, both, and nonarrhythmic syncope) and the treatment
(pacing, drugs, both, neither). The total number of months
of survival, withappropriate quality adjustments (see later),
was calculatedfor each cohort. Those totals, divided by the
initial cohort size, were used as an approximation of the
"quality-adjusted life expectancy."
At any given moment, each patient is in one of three
major states (Fig. 2): I) not having AV block, 2) having
AV block, or 3) dead. The likelihood of transition between
one state and anotherdependson well defined probabilities.
A patientwithoutAV blockmaybe "unpaced" or "paced";
that is, a permanent cardiac pacemaker may already have
been implanted. The patient with a pacemaker is subject to
complications, generator changes and sudden pacemaker
failure . In those patients who have symptoms related to
bradycardia, pacemaker implantation providessymptomatic
improvement and prevents asystole if AV block develops.
If the heart is not paced, sudden death can occur when AV
block develops. We assume that a pacemaker will be im-
planted when AV block is diagnosed if the heart is unpaced
at that time. Finally. a patient may die from several causes:
I) bradyarrhythmia, 2) ventricular tachyarrhythmia, 3) the
general spectrum of other risks faced by healthy members
of the general population of the patient's age and sex, or
4) some other disease process, cardiac or noncardiac, for
example, diabetes or cancer. The "temporary states" rep-
resented by shaded circles in Figure 2 (acute AV block,
pacemaker implantation, generator changes and pacemaker
failures) were assumed to last only a single month.
We did not use a first order Markov model in this case,
that is, the probability of death in the general population
was modeled to increase exponentially with age. Although
bifascicular block can be progressive, the availablereported
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Figure 2. Markov model. Four major clinical states are depicted:
no AV block not paced, no AV block paced, AV block, and dead.
At Time i a cohort member is in one of these states of health. At
Time i+ I the patient has either remained in the starting state
(heavy vertical arrows) or changed to another major state. The
patient with no AV block can remain in that status, develop acute
AV block if the heart is not paced (shaded oval), transit to stable
AV block if empiric pacing is instituted, or die as a result of a
number of causes. All patients with stable AV block will have
pacing. The shaded ovals represent temporary events associated
with a short-term decrement in quality of life and an increased
risk of death: I) acute AV block as described, and 2) pacemaker
events and complications. The asterisk (*) signifies death due to
underlying disease, cardiac arrhythmia other than AV block, or
general population (Gompertz) mortality. Abbreviations as in Fig-
ure I.
Table 5. Markov Transition Probabilities
data (Tables I and 2) do not support a specific model of
progression. We therefore chose to use a constant, average
transition probability from bifascicular to AV block. AV
block itself confers a constant added risk of death on a
patient.
Variables of the Markov model (Table 5). We relied
heavily on the report by McAnulty et al. (26) for natural
history, and on expert opinion for the distribution of cause
of syncope and risks of sudden death. Of patients with
chronic bifascicular heart block and symptoms related to
bradyarrhythmias, 20% will develop AV block within 5
years and will be subject to a 10% risk of dying before a
pacemaker can be implanted. With AV block, the excess
From
Chronic bifascicular block (syncope)
Chronic bifascicular block (syncope)
AV block
Pacemaker
General population
Underlying illness
To
AV block
Bradyarrhythmic
Cardiac death
Pacemaker failure
Death (all causes)"
Death due to that illness
Transitions/ 1,000 Patient Months
3.7
1.0
7.6
10
Age 65: 2.3
Age 70: 3.6
Age 75: 5.6
0**
25.0 16.7
20.8 12.5
16.7 12.5
8.3 8.3
4.2 0
Bradyarrhythmia/conduction disturbance
Ventricular tachyarrhythmia
Both
Nonarrhythmic syncope
Cardiac death
Cardiac death
Cardiac death
Cardiac death
Therapy
No pacing
Pacing
No drugs
Drugs
Electrophysiologic
testing and drugs
No pacing or
electrophysiologic
testing
Pacing
Electrophysiologic
testing and drugs
Electrophysiologic
testing. drugs. pacing
All therapies
Poor Left
Ventricular
Ejection Fraction
12.5
8.3
25.0
20.8
8.3
Normal Left
Ventricular
Ejection Fraction
8.3
4.2
16.7
12.5
4.2
*Gompenzmodel: 1- exp[-7.3 x 10- 5 x exp(8.05 x 10. 2 agej]. **Baselineload.
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with ventricular tachyarrhythmias, in addition to bradyar-
rhythmia, sudden death is an additional "load," but one
accounted for explicitly in the model.
Effects on quality of life. Pacemaker therapy improves
a patient' s quality of life when it relieves symptoms (that
is, syncope) or lessens anxiety by providing "insurance "
against life-threatening bradycardia. It can diminish a pa-
tient' s quality of life by creating concern about being de-
pendent on a pacemaker and the potential for that device
failing (54) and by necessitating the inconvenience of on-
going follow-up and monitoring. We diminished the quality
of life of a patient who continues to experience syncope;
each month with syncope was counted as only a fraction of
a " well" month. For example, if syncope diminishedqual-
ity of life by 25%, then each month of survival with con-
tinued symptoms was adjusted for this quality and counted
as 3 weeks of survival. Approximately 20% of patients
receiving antiarrhythmic drugs experience substantial side
effects that reduce their quality of life by approximately the
same amount as patients having recurrent syncope, so a 5%
overall quality of life adjustment was made for antiarrhyth-
mic therapy. In the same fashion, whenever the patient had
a pacemaker implantation or course of drug therapy, the
quality of life for all subsequent months was slightly di-
minished to reflect anxiety and the necessity for follow-up.
For example, if drug therapy diminished quality of life by
5%. then each year of survival with therapy was counted
as only 49.4 quality-adjusted weeks. If the patient was un-
fortunate enough to continue to have syncope after antiar-
rhythmic therapy, then the quality of life was diminished
by both factors. For example, if the mentioned factors of
25 and 5%, respectively , were both operative, then quality
would be adjusted to 75% x 95% or roughly 70% of full
quality: each year would count as only 36 quality-adjusted
weeks. Pacemaker complications, pacemaker failure and
routine battery changes wereassumedto diminishthe quality
of life only for the month in which the complication or
hospitalization occurred.
We administered a questionnaire to 16 cardiologists at-
tending a pacemaker conference and assigned baseline val-
ues for the definedquality-adjustmentfactors based on their
Table6, Quality of Life With Various Therapiesmortality is 9.1%/year (or 7.6 deathsll,OOO patient months).
We assumed that the annual risk of dying from .'general
causes" increasesexponentiallywith age, roughlydoubling
every 8 years, as it does in the general population(following
Gompertz's law (51,52). We used reported mortality data
for the United States (53) to derive the regression coeffi-
cients for the Gompertz equation.
In assessing the incidence of pacemaker complications ,
wedeliberatelychose high values to bias the analysis against
aggressive implantation. We assumed that I) pacemaker
insertion complications result in a 0.1% mortality rate, 2)
the battery life of current lithium units is 6 years, and 3)
unscheduled pacemaker failure occurs in I% of units over
their effective lifetime. At the time of pacemaker failure,
we assumed a 20% risk of dying if AV block was present
because the patient's intrinsic pacemaker activity would have
been suppressed.
The risk of sudden death under the various syncopal
etiologies and treatment plans in Table 5 was estimated by
an expert electrophysiologist and also represents the ex-
pected number of deaths per 1,000 patient months.
Those patients whose symptoms are not pacemaker re-
sponsive were assumed to have some illness that did not
diminish their life expectancy beyond the effects of their
underlyingcardiacdisease, as manifestedby the bifascicular
block. This assumption does not introduce any bias into
either the threshold or cost-effectiveness calculations (see
later).
Threshold model. In this analysis, we are investigating
the rationale for implantinga pacemakeror performingelec-
trophysiologic testing in symptomatic patients without doc-
umented AV block . Thus, pacemaker implantat ion mayor
may not be effective in any individual patient. Since this
probability is of great importance, we repeated our analysis
for a broad spectrum of probabilities of bradyarrhythmia
and ventricular tachyarrhythmia. The probability of pace-
maker-responsive symptoms above which aggressive ther-
apy is preferable is called the threshold probability (15) for
pacing.
Concept of "load." Patients with syncope related to a
bradyarrhythmia sometimes have no underlying cardiac or
other serious disease. In that situation, their only risk of
death, over and above those facing the general population,
is related to bradyarrhythmias. More commonly, these pa-
tients have underlying cardiovascular disease. Then, the
potential benefits of pacemaker therapy are limited by these
other processes; that is, pacemaker therapy cannot diminish
these additional risks. In fact, risks not responsive to pace-
maker therapy are not limited to cardiovascular disease; the
effects of cancer would be analogous. The term "load"
describes these noncorrectable risks. Obviously, the higher
the load, the shorter will be the patient' s survival. Thus.
the efficacy or benefit of pacing, as measured by prolonged
survival, will be diminished if the load increases. In patients
Therapy
Pacemaker
Drugs
Both pacemaker and drugs
No therapy
Pacemaker
Drugs
Both pacemaker and drugs
Hospitalization for any reason
Clinical Status
No syncope
No syncope
No syncope
Syncope
Syncope
Syncope
Syncope
Quality of Life
(% month)
100
95
90
75
70
65
60
50
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responses. Collectively, these physicians treat more than
4,000 patients with a permanent cardiac pacemaker. They
were asked to report their perceptions of the loss of quality
of life that their patients experience as consequences of
pacemaker therapy. Their assessments of the quality of life
in various clinical states are summarized in Table 6.
Costs. We based our estimates of medical costs on 1985
charges at a teaching hospital. Pacemaker implantation cost
$15,370 (that is, hardware $4,100, professional fees $1,880,
and hospital charges $9,390 for a 6 day admission). Gen-
erator changes cost $11,130 (that is, hardware $2,000,
professional fees $970 and hospital charges $8,160 for a 5
day admission). Charges for replacement were less, on av-
erage, because some companies provide replacement units
free as a part of their warranty policy and because the elec-
trode is not usually replaced.
Average electrophysiologic testing charges depended on
the results of the study. If a pacemaker-responsive lesion
was discovered, a pacemaker was implanted at the time of
testing, yielding hospital charges of $11,800 and profes-
sional fees of $3,080 for an 8 day admission, plus the
pacemaker cost of $4,100, for a total of $18,980. If ven-
tricular tachyarrhythmia was discovered, the cost totaled
$14, 140 (that is, $10,990 for two studies and professional
fees of $3,150, over a 9 day admission). If the study was
nondiagnostic, the charges were $4,980 (hospital charges
totaled $3,660 and professional fees $1,320 for a 3 day
admission). Outpatient visits every 4 months cost $75, in-
cluding the cost of an electrocardiogram. Monthly transtel-
ephonic monitoring cost $45. Drug therapy for ventricular
arrhythmias (procainamide and tocainide) cost $140/month.
Table 7. Baseline Results: 65 Year Old Man
Discounting. Future costs were discounted at 5%/year
to reflect the fact that if an expense can be deferred, the
requisite resources can be invested to yield returns before
the costs are incurred. Future years of life (that is, benefits)
were also discounted to maintain internal consistency in our
analysis (55). The discounting of future benefits reflects both
risk aversion (56) and the decreasing marginal value of life
associated with aging.
Marginal cost-effectiveness. The conservative strategy
of implanting a pacemaker only when AV block is docu-
mented should prevent subsequent bradyarrhythmic events.
The aggressive strategy of implanting a pacemaker before
AV block is documented or giving empiric drug therapy,
or both, might provide some additional (or marginal) sur-
vival at some additional (or marginal) cost. These additional
costs are incurred because the pacemaker would be im-
planted sooner in patients who eventually develop AV block
and in some patients who would never develop AV block
and would not receive a pacemaker under the conservative
strategy.
Results
Expected costs, survival and quality of life. Although
many analyses were performed in this study, only a selection
will be reported here. We consider the case of a 65 year
old man with syncope of unknown origin. Table 7 displays
the results using baseline data, in the settings of I) normal
left ventricular function and 2) decreased left ventricular
ejection fraction in the setting of coronary artery disease.
The patient with normal left ventricular function is most
Marginal Marginal Marginal
Expected Quality-Adjusted Cost* Quality-Adjusted Cost-Effectiveness*t
Strategy Costs ($) Survival (Mo) Survival (Mo) ($) Survival* ($/Year)
Normal Left Ventricular Function
Observation 3,260 1/6.6 60.1
Drugs 14,800 117.8 54.9 11.540 -5.2
Electrophysiologic 27,450 134.4 73.8 24,190 13.7 21,200
testing
Pacing 41,710 137.1 76.3 14,260 2.5 68,400
Both pacing and 55,760 138.3 70.9 14,050 -5.4
drugs
Poor Left Ventricular Function
Observation 1,360 61.4 35.8
Drugs 8,290 64.1 37.3 6,930 1.5 55,400
Electrophysiologic 25,190 85.2 53.8 16,900 16.5 12,300
testing
Pacing 26,730 67.8 40.6 1,540 -13.2
Both pacing and 34,930 70.5 42.7 9,740 -11.1
drugs
*Compared with prior nondominated strategy (see text for details). tFinal column is calculated by dividing column 5 by column 6 and multiplying
by 12.
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Figure 3. Cost-effectiveness plot. The closed points represent
plausible strategies, the open points dominated strategies. A, Pa-
tient with normal left ventricularfunction. Theplausible strategies,
in order of cost and effectiveness, are observation (Obs.), elec-
trophysiologic testing (EPS), and pacing, connected by a solid
line. B, Patient with poor left ventricular function. The effective
strategies are observation, drugs and electrophysiologic testing.
However, the marginal cost-effectiveness of drugs with respect to
observation is higher (dotted line) than thatof electrophysiologic
testing versus observation (solid line). Thus, electrophysiologic
testing is more cost-effective than drug therapy (see text for de-
tails). The marginal cost/effectiveness ratio refers to the slope of
lines connecting plausible points; the lower the slope, the more
cost-effective the strategy.
$35,000
$30,000
$25,000
s
$20,000
'"0
o $15,000
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likely to have a bradyarrhythmia or conduction defect (Table
4). Empiric treatment with both antiarrhythmic agents and
a pacemaker provides the greatest survival (\ 38 months),
at a discounted cost of nearly $56,000. Empiric pacing offers
nearly the same survival at substantially less cost ($42,000).
A diagnostic approach using electrophysiologic testing of-
fers a slightly lower survival rate, at even less cost. Empiric
drug therapy and observation are associated with substan-
tially less expected survival. When the quality of a patient's
life is considered, rather than the expected survival, the
effectiveness of therapy is decreased. In this case, the ex-
pected utility of empiric drug therapy falls below that of
observation, while empiric combined therapy falls below
empiric pacing and electrophysiologic testing (Fig. 3A).
In the setting of poor ventricular function and a history
of coronary artery disease, ventricular tachyarrhythmia is
the most likely cause, while bradyarrhythmic conduction
disturbances alone comprise only 25% of causes (Table 4).
Because of the increased probability of ventricular arrhyth-
mias, electrophysiologic testing offers the greatest survival
time in this type of patient (Table 7). Costs are less than in
patients with normal left ventricular function, because sur-
vival time is shorter. Empiric therapy with both antiarrhyth-
mic agents and pacing is again the most expensive. Ad-
justing for quality of life does not change the ordering of
strategies (Fig. 3B).
Marginal cost/effectiveness ratio. Because we live in
a world of limited resources, it is not always possible to
provide every patient with the medical therapy that maxi-
mizes his or her individual survival. In choosing among
feasible alternatives the physician and the health policy an-
alyst should consider some metric that compares the relative
cost and effectiveness of competing strategies. One appro-
priate metric is the marginal cost/effectiveness ratio which,
in this case, expresses how much additional survival can be
"bought" for each additional dollar expended. (If one strat-
egy costs more than another strategy and provides less ef-
fectiveness, then the more costly strategy is said to be dom-
inated and can be rejected from further consideration.)
Table 7 lists the marginal cost-effectiveness of each strat-
egy, that is, the difference in its quality-adjusted survival
and that of the next cheapest strategy. In the patient with
normal left ventricular function, pacing offers 2.5 additional
quality-adjusted months of survival compared with electro-
physiologic testing. If any strategy provides a negative mar-
ginal effectiveness (for example, "drugs" and "both pacing
and drugs"), it is dominated and rejected. Thus, the mar-
ginal effectiveness of electrophysiologic testing is 13.7 months
because it is compared with observation and not empiric
drug therapy, which has been rejected. In considering the
marginal cost of each plausible strategy, empiric drug ther-
apy and empiric dual therapy are again rejected because
they are dominated. Thus, the marginal cost of electro-
physiologic testing is $24,190 ($27,450 minus $3,260). From
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Figure 4. One-waysensitivityanalyses in the patient with normal
left ventricular function. The horizontal axes represent the prob-
ability of bradyarrhythmic etiology of syncope. The vertical lines
illustrate the threshold probabilities; the arrows representbaseline
conditions. A, Vertical axis represents the quality-adjusted life
expectancy. B, Vertical axis represents marginal (Marg.) cost-
effectiveness of different strategies. Lines represent comparisons
between invasive strategies and observation, Abbreviations as in
Figure I; QALY = quality-adjusted life-year.
rhythmias is 10%; for probabilities below that value, empiric
pacing offers the highest quality-adjusted survival; for prob-
abilities above that threshold, electrophysiologic testing is
the best strategy in terms of survival.
The marginal cost-effectiveness will be affected by the
probability ofbradyarrhythmia or ventricular tachyarrhyth-
the ratio between marginal cost and marginal effectiveness,
we can express the results as additional dollars per additional
life-year saved. The three plausible strategies for a man with
normal left ventricular function are observation, electro-
physiologic testing and empiric pacing. The marginal
cost/effectiveness ratio of electrophysiologic testing is
$21,200/additional quality-adjusted life-year gained; the
marginal cost/effectiveness ratio of empiric pacing is
$68,4OO/quality-adjusted year.
In the patient with poor left ventricular function (Table
7), the plausible strategies are observation, empiric drug
therapy ($55,400/quality-adjusted year), and electrophysi-
ologic testing ($12,300/quality-adjusted year). Because
electrophysiologic testing has a lower marginal
cost/effectiveness ratio than empiric drugs, one should be
willing to perform electrophysiologic testing if one were
willing to give empiric drug therapy and if one had sufficient
resources, because society would receive more effectiveness
for each dollar spent. Thus, it makes sense to compare
electrophysiologic testing with observation. The marginal
cost is $23,830 and the marginal effectiveness is 18 quality-
adjusted months. Thus, the cost/effectiveness ratio is
$15,900/quality-adjusted year. These relations are displayed
in the graphic representations of Figure 3.
Sensitivity analyses. We examined the effect of changes
in the assumptions of the analysis on the results. We illus-
trate these sensitivity analyses by demonstrating the effect
of two probabilities-the likelihood of bradyarrhythymia
and the likelihood of ventricular tachyarrhythmia-which,
in any given patient, are likely the "softest" data in the
analysis. Figure 4 shows the results in a patient with normal
left ventricular function; in that case, bradyarrhythmia is
the most likely etiology. Figure 5 shows the results in a
patient with impaired left ventricular function; in that case,
ventricular tachyarrhythmia is the most likely etiology. In
both analyses, the probabilities of the other diagnoses are
varied proportionately.
In the patient with normal left ventricular function (Fig.
4), expected survival increases for any strategy that includes
pacing (that is, empiric pacing, empiric dual therapy and
electrophysiologic testing) because the probability of ven-
tricular tachyarrhythmia (the most life-threatening etiology)
declines as the probability of bradyarrhythmia increases.
For probabilities of bradyarrhythmia greater than 38%, em-
piric pacing offers the greatest quality-adjusted survival; for
probabilities less than 38%, electrophysiologic testing offers
the greatest quality-adjusted survival. This crossover point
is called the threshold probability. In the patient with de-
pressed left ventricular function (Fig. 5), expected survival
declines for all strategies except electrophysiologic testing
as the probability of ventricular tachyarrhythmia increases.
The expected survival with electrophysiologic testing in-
creases because appropriate drug therapy can be given. In
this case, the threshold probability of ventricular tachyar-
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Figure 5. One-way sensitivity analyses in the patient with poor
left ventricular (Vent.) function . The horizontal axes represent
the probabilit y of tachyarrh ythmic origin of syncope. Format as
in Figure 4. Abbreviations as in Figures I and 4.
mia (Fig . 4 and 5). In the case of normal left ventricular
function (Fig. 4), electrophysiologic testing is the mostcost-
effective strategy if the probability of bradyarrhythmia is
below 72%. Above the threshold, empiric pacing is most
cost-effective. Note that the strategy of empiric dual therapy
is always less cost-effective that either electrophysiologic
testing or empiric pacing. If the probability of bradyar-
rhythmia is below 38%, electrophysiologic testing is both
most effective and most cost-effective; if the probability is
Discussion
Cardiac pacemakers are associated with few medicalrisks
and provideprolonged lifeexpectancy and improvedquality
of life for many patients with symptomatic brady-
arrhythmias. Nevertheless, a great deal of attention has been
focused on widespread use of this technology, in part be-
cause it is considered expensive and in part because sharply
defined indications were slow to be established. Guidelines
issued by the Health Care Financing Administration (57)
promote the general policy of reimbursing pacemaker im-
plantations only when a clear relation between bradycardia
and symptoms has been established. This requirement has
led some clinicians to recommend invasive electrophysio-
logic studies to establish such a relation. Although such
testing is relatively low risk (much like the empiric use of
pacemakers), it too is quite expensive. Thus, one must ask
whether such testing protocols are a cost-effective use of
the nation's resources or whether other strategies should be
considered.
between 38 and 72%, than pacing is most effective but
electrophysiologic testing is most cost-effective; if the prob-
ability is above 72%, then empiric pacing is both most
effective and most cost-effective. The situation is different
in the case of impaired left ventricular function (Fig. 5).
Electrophysiologic testing is most cost-effective until the
probability of ventricular tachyarrhythmias exceeds 92%;
beyond that value. empiric drug therapy is most cost-effec-
tive but not the mosteffective. Below a probability of 10%,
empiric pacing is most effective but electrophysiologic test-
ing remains most cost-effective.
Another analysis ol parti cular interest is the effect (~l
simultaneous change in both the likelihood of ventricular
tachyarrhythmias and the probability of bradyarrhythmic
conduction defects (Fig. 6). In terms of quality-adjusted
expected survival, observation is the best option at low
probabilities of bradyarrhythmic conduction disturbanceand
ventricular tachyarrhythmia (that is, near the origin, where
the most likely etiology is nonarrhythmic syncope). At rel-
atively high likelihoodsof bradyarrhythmic disease and low
likelihoods of ventricular lesions, empiric pacemaker ther-
apy is most effective (but not necessarily cost-effective, see
earlier). At higher likelihoods of ventricular disease and
lower chances of bradyarrhythmic syncope, electrophysio-
logic testing offers the greater expected survival.
The effects of age and co-morbidity (or load ) on the
expected survival and quality (ijlife were studied ill several
Markov alialyses . In virtually all cases the absolute survival
decreased for all strategies proportionately. Inasmuch as
costs tend to be high at the outset (that is, hospitalization
and initial pacing), cost-effectiveness varies directly with
age and co-morbidity.
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Figure 6. Two-way sensitivity analyses of the probabilities of
bradyarrhythmia and ventricular (Vent.) tachyarrhythmia. Each
point inside thecurved triangle defines a unique combination of
these probabilities; the region in which the point lies defines the
most effective strategy, in terms of quality-adjusted life expect-
ancy. The blackdot oneach figure represents baseline conditions .
A and B represent a patient with normal and poor left ventricular
function, respectively.
Modeling Issues
This review demonstrates how decision analysis, cost-
effectiveness analysis and Markovmodeling techniques can
be used to approach vexingquestions in cardiology. Several
basic principlesunderlie these analytic techniques. First and
foremost, such models are explicit. Each assumption is listed
and quantitated-not to provide greater accuracy-but to
allow the physician, the policy analyst and even the patient
to understand the reasoning that lies behind these conclu-
sions.
Decision analyses. A standard decision analysis in-
volves five basic steps. I) A model is constructed that rep-
resentsa well focused question in sufficient detail to provide
reasonable insights. 2) The probability of each potential
diagnostic and therapeutic outcome is assessed, from ob-
jective data (whenthey are available in the published reports
or in clinical data bases) or from the subjectiveopinions of
experts. 3) The various potential outcomes are delineated
and assigned relative value on a consistent scale. Often,
such scales involve consideration of both the quantity and
quality of life. 4) The expected value of each therapeutic
strategy is calculated using two basic rules: when a choice
can be made, pick the betteroption; when a chance is faced,
assign an expected value based on the weighted average of
the values of the potential outcomes, where the weighting
factors are the likelihoods of the outcomes' occurring. 5)
Finally, extensive sensitivity analyses are performed to de-
termine howtheconclusions of the analysiswould be changed
if the assumptions were different but still plausible.
Estimation of diagnosis and prognosis. In this analysis,
two further modeling complexities were added. Our model
combines a decision tree, to represent the diagnostic pos-
sibilities and the results of electrophysiologic testing, and
a Markov or state transition model to estimate prognosis.
In a Markov process model , the analyst specifies a limited
set of states of health, an incremental utility for each state
and a set of transition probabilities that govern the flow of
patients fromone state to another. A cohort stimulationthen
follows a population of patientsas they movefrom one state
to another, until all members of the simulatedcohort "die."
The expected value assigned to such a cohort's prognosis
is then the sum of the products of each incremental utility
times the number of patients in each state. Such models
simply represent a compact formulation of extremely deep
decision trees. Our model involved only four states of health.
If we used a classic decision tree representation, the tree
would have contained several thousand nodes and would
have required four or five journal pages to represent. Trees
of such complexity would provide the clinician with little
insight and would be subject to many hidden errors.
Cost-effectiveness analysis. Second, we performed a
cost-effectiveness analysis so we were actually using two
separate value scales (dollars and quality-adjusted life-years),
rather than combining them into a single scale. Cost-effec-
tiveness analysis can identify some strategies that are in-
ferior in terms of both cost and effectiveness (for example,
the empiric use of drugs and pacing in a patient with symp-
tomatic bifascicular block and normal left ventricular func-
tion). Such strategies are said to be "dominated." When
such strategies are removed from consideration, one is left
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with an array of options that can be ordered to provide
increasing effectiveness (for example. survival) at increas-
ing cost. There are no absolute guidelines about how much
is too much to spend to gain an additional unit of effec-
tiveness, that is, an additional year of survival. By com-
paring the analytic result to similar analyses of both a com-
monly accepted therapy (such as coronary artery surgery)
and a therapy acknowledged to be very expensive (such as
transplantation), the physician and analyst can gamer a
framework for comparison.
Complexity of the analytic model: role of computer
support. Decision analytic models are constructed not to
provide a single answer but to provide insights into a prob-
lem and must be explored under a variety of assumptions .
If such models are of substantial complexity (as is the case
here), their design, analysis, debugging and interpretation
can involve a significant computational burden. The ana-
lysts' ability to construct and use such models then becomes
limited by the feasibility of performing such calculations.
Computational support is available in three main ways. First,
special computer programs can be written to analyze a spe-
cific model (58,59). Second, general decision tree analysis
software can be used (60-63). Third, general productivity
software such as spreadsheets can be used. ln fact, spread-
sheet programs can be particularly useful in creating Markov
models.
Clinical Issues
Empiric pacemaker therapy versus electrophysiologic
testing in patients with normal left ventricular function.
The relative benefit of electrophysiologic testing must de-
pend on the likelihood that a pacemaker-responsiveetiology
of the patient's symptoms is, in fact, present and on the
likelihood that electrophysiologic testing will identify an-
other treatable cause. In this analysis, we examined the
question of empiric pacemaker therapy versus electrophys-
iologic testing in symptomatic patients with bifascicularblock
in whom noninvasive evaluation has been unrevealing. Be-
cause these patients have a higher probability of pacemaker-
responsive syncope than do most patients with syncope. we
expected empiric pacing to be a reasonable strategy. Our
analytic results were quite surprising, however. Even in
patients with normal left ventricular function (in whom the
likelihood of a bradycardia was assumed to be 50%), elec-
trophysiologic testing was more cost-effective than empiric
pacing; the latter strategy would provide a very small ad-
ditional survival compared with electrophysiologic testing
(about 2.5 quality-adjusted months) but would cost, on av-
erage, an additional $5,700 because some patients who do
not need a pacemaker would receive one. Thus, society
could prolong such a patient's survival, but at the exorbitant
cost of $68,000 for each life-year gained. In comparison,
the strategy of performingelectrophysiologic testing in such
patients, compared with conservative management, would
cost only $21.000 per quality-adjusted life-year gained. The
latter costs are very much in line with other accepted ther-
apies: $20.000/quality-adjusted year for coronary bypass in
patients with moderate to severe angina (17) and
$15 ,OOO/quality-adjusted year for antihypertensive therapy
in moderately hypertensive patients (16). Electrophysiologic
testing is usually limited to a few major tertiary centers. If
e1ectrophysiologic testing is not available for a given patient,
one should compare the cost-effectivenessof empiric pacing
with that of observation alone: empiric pacing provides im-
proved survival (over 16 quality-adjusted months) at a cost
of $28.OOO/quality-adjusted year.
Electrophysiologic testing versus empiric pacing in
the patient with impaired left ventricular function. The
situation is quite different in the patient with impaired left
ventricular function in whomelectrophysiologic testing pro-
vides substantially more survival (1 7 quality-adjusted months)
compared with empiric pacing. Here, not only is electro-
physiologic testing the most cost-effective strategy, but sub-
stantial effort should be made to seek electrophysiologic
testing if it is not available locally. If empiric pacing is
performed. the marginal cost would be $60,000 per addi-
tional year of life gained. It would, in fact, be more cost-
effective ($31 ,OOO/quality-adjusted year) to use empiric drug
therapy in these patients because the likelihood of ventric-
ular tachyarrhythmia is substantially higher than in patients
with normal left ventricular function (45 versus 10%).
Role of sinus node dysfunction . Because roughly 15%
of patients with symptomatic bifascicular block have sinus
node dysfunction and will experience improved quality of
life (but no increase in overall survival) with pacemaker
therapy. empiric pacing will provide a slightly greater qual-
ity-adjusted survival than our baseline estimate; quality-
adjusted survival will be approximately 6 months longer,
making the marginal cost-effectiveness of empiric pacing
compared to electrophysiologic testing only $20,OOO/quality-
adjusted year, a more acceptable allocation of resources.
What if pacing were less expensive? Although the life-
time costs of empiric pacing may seem high ($42,000 in a
65 year old man with normal left ventricular function ), they
were based on the actual billing records in a teaching hos-
pital. Approximately 35% of these costs were ascribed to
initial implantation. approximately 20% were ascribed to
monitoring costs and fully 45% of these costs were ascribed
to subsequent battery replacements. If the costs of implan-
tation and replacement could be lowered (by using less
expensive hardware, decreasing the hospital length of stay
or increasing the average time between replacements), then
the costs of both empiric pacing and electrophysiologic test-
ing would decline, but a proportionately greater decline
would be seen in the empiric pacing strategy. Nevertheless,
electrophysiologic testing is always morecost-effectivethan
is empiric pacing, although the empiric strategy will "buy"
934 BECK ET AL.
THRESHOLD FOR PACING IN BIFASCICULAR BLOCK
lACC Vol. 9. No. 4
April 1987:920- 35
additional survival in the patient with normal left ventricular
function. If the cost of pacemaker implantation and battery
changes can be decreased by 6%, then empiric pacing pro-
vides additional survival at a cost of $65,OOO/quality-ad-
justed year; if costs decrease by 13%, then additional sur-
vival is available at $53,OOO/quality-adjusted year; if costs
drop by 20%, then additional survival is available at
$17,OOO/quality-adjusted year, a value very much in line
with accepted therapies. Thus, the strategy of aggressive
empiric pacing should become more and more socially ac-
ceptable as the cost of pacing decreases.
Implications for health policy. The analysis reported
here provides several important insights for clinicians and
for individuals who determine health policy. First, there are
some circumstances in which empiric pacing would be both
more effective, and even more cost-effective, than electro-
physiologic testing. In patients with normal left ventricular
function, empiric pacing provides longer survival if the
probability of bradyarrhythmia exceeds 38% (Fig. 4a) but
is not more cost-effective than electrophysiologic testing
until that probability exceeds 72% (Fig. 4b). Second, be-
cause the majority of the costs of pacing can be ascribed to
follow-up and battery replacement, the lifetime costs will
be even higher in younger patients who will incur these
costs for a much longer period. This effect can be seen in
Table 7. where the costs of empiric pacing are far higher
in the patient with normal left ventricular function who will
experience twice the survival time of patients withdepressed
ventricular function. Finally, comparing Figures 6A and 6B,
we can see that the circumstances in which empiric pacing
would provide enhanced survival are not very different in
the setting of normaland depressed left ventricularfunction.
Rather, the major difference between these two circum-
stances is the likelihood of ventricular arrhythmia, a diag-
nosis more than four times as likely in the setting of de-
pressed left ventricular function.
Conclusions. From the standpoint of national policy about
cardiac pacemakers, the most important effect of a decision
analytic model should be neither blind acceptance nor ad-
herence to its conclusions. Rather, we present this model
to provoke active yet focused discussion of these issues, not
solely on the basis of the conclusions of experts but also
on the basis of the " facts" - both objective and subjec-
tive-that underlie such opinions. Although the model pre-
sented here focused on a narrow spectrum of patients (those
with symptomatic bifascicular block), its basic structure is
relevant to a far broaderspectrum of clinical questions about
the indications for cardiac pacing. Such a model could be
readily adapted to other settings in which there is disagree-
ment about the need for pacing. Certainly, there may well
be settings in which pacing is overutilized, but the debate
about its indications should be based on clearly defined
assumptions and logic, not just on opinion and anecdotal
reports. Because absolute certainty is rare in the practice of
medicine, both the clinician and the policy analyst must
recognize that firm documentation of the relation between
symptoms and arrhythmias cannot always be established.
An overly rigid requirement for diagnostic certainty may
deprive some patients of important therapeutic benefits and
may occasionally engender greater expense.
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